EDITORIAL for BJP themed issue “noncoding RNA therapeutics” DOI Open Access
Yvan Devaux, Serena Zacchigna, Rainer Schulz

et al.

British Journal of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 21, 2024

Several RNA-type molecules have reached the market recently, and use of noncoding RNAs for therapeutic purposes is a booming field pharmacology drug development (Caporali et al., 2024; Dzau & Hodgkinson, Nemeth Parhiz Tang Khvorova, 2024). Leading authors provide joint effort to discuss recent progress future perspectives on this emerging pharmacology. The work presented in Themed Issue mainly stems from networking activities within three Cooperation Science Technology (COST) Actions, funded by European Commission. Most articles included are members these COST Actions. Cardioprotection Action 2017–2022 had objective facilitate translation novel cardioprotective therapies clinic (www.cardioprotection.eu) (Ferdinandy 2023; Hausenloy Heusch, 2019). CardioRNA 2018–2023 aimed catalyse collaborative research cardiovascular RNA (www.cardiorna.eu) (Badimon Devaux, 2020). AtheroNET 2022–2026 aims delve into potential multiomics better understand treat atherosclerotic disease (www.atheronet.eu) (Sopic, Kararigas, 2023). On 7 October 2020, Royal Swedish Academy Sciences awarded Nobel Prize Chemistry Professors Doudna Charpentier their breakthrough CRISPR technology (N. P. O. A., 2023a). Since then, extensive has shown very promising results modern medicine (Pacesa 2 2023, Physiology or Medicine was Karikó Weissman ground-breaking mRNA modification 2023b). One year later, 7th, 2024, Ambros Ruvkun microRNAs These prizes reflect keen interest research. Recent technical innovations boosted mRNA-based therapies, including quick vaccines against SARS-CoV2. In regard, usefulness extends beyond diagnosis treatment. Both coding possess high biomarker (Devaux 2015; Winkle 2021). Developing "theranostics" ("theragnostics") approaches based diagnose, monitor progression holds significant improve personalized healthcare Vilne, especially represent actionable biomarkers, useful diagnosis, prediction monitoring of, example, ischaemic heart Using both early accurate disease-modifying may help advance clinical outcomes (theranostics concept; Figure 1). We believe that therapeutics patients suffering but also any other where homeostasis dysregulated. value as drugs targets been thoroughly discussed illustrated invited review British Journal Pharmacology. A Spanish team led Dr. David de Gonzalo-Calvo emphasizes mitigate persistent pulmonary complications after COVID-19 (García-Hidalgo Dr Paola Di Pietro colleagues report capacity miRNA-1-3p predict severity hospitalized (Di Yvan Devaux Luxembourg reviews current knowledge atherosclerosis (Sopić 2024), while Drs. Gerhild Euler Mariana Parahuleva focus monocytic treatment (Euler Parahuleva, Andrew Baker covers vascular smooth muscle cell dysfunction (Brown Aida Collado co-workers study miR-210 diabetes-associated endothelial (Collado An international focusses circular role cardiac remodelling (Bibi Exploitation cancer therapy-related cardiotoxicity covered Gabriela Kuster her Switzerland (Bernasconi Kuster, Hungarian Prof. Peter Ferdinandy discusses avoid off-target effects small (Bereczki 2024) reports two translational studies aiming test miR-125b* murine model acute myocardial infarction (Szabados miR-450a pig without with intervention, is, preconditioning (Nagy Finally, Italian group Serena Zacchigna compares currently available discovery platforms (Ciucci Overall, gathers original diverse groups supporting pharmacological agents population health. Editors call accelerated field. YD drafted manuscript; SZ RS reviewed edited manuscript. This Editorial upon CA16225 (www.cardioprotection.eu/), CA17129 CA21153 (European Technology; www.cost.eu). Y. D. filled patents related diagnostic member Scientific Advisory Board molecular company Firalis SA.

Language: Английский

The miR-21-5p/DUSP8/MAPK signaling pathway mediates inflammation and apoptosis in vascular endothelial cells induced by intermittent hypoxia and contributes to the protective effects of N-acetylcysteine DOI
Yan Zhao, Renjun Lv,

Yao He

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: 997, P. 177462 - 177462

Published: March 7, 2025

Language: Английский

Citations

1
SNHG family lncRNAs: key players in the breast cancer progression and immune cell’s modulation DOI

Mohamed J. Saadh,

Junainah Abd Hamid,

H. Malathi

et al.

Experimental Cell Research, Journal Year: 2025, Volume and Issue: unknown, P. 114531 - 114531

Published: March 1, 2025

Language: Английский

Citations

1
RNA Biopesticides: A Cutting‐Edge Approach to Combatting Aquaculture Diseases and Ensuring Food Security DOI Creative Commons
Qiu Li, Lixing Huang

Modern Agriculture, Journal Year: 2024, Volume and Issue: 2(2)

Published: Dec. 1, 2024

ABSTRACT Aquaculture plays a crucial role in addressing global nutritional demands and economic growth. However, the high‐density nature of aquaculture presents significant challenges, including disease outbreaks that hinder production impact profitability. Diseases are major concern, with losses exceeding 25%, new pathogens emerging each year. Traditional pharmaceuticals struggle drug resistance environmental harm, raising food safety concerns due to chemical residues. RNA‐based biopesticides offer promising solution by targeting specific mRNA sequences pathogens, thereby inhibiting their growth reproduction. These biopesticides, siRNA dsRNA, have shown great potential managing diseases. With high specificity minimal impact, RNA provide an innovative, sustainable approach combating diseases aquaculture, enhancing both security safety.

Language: Английский

Citations

8
MAT2A Knockdown Enhances Recombinant Protein Expression in Transgenic CHO Cells Through Regulation of Cell Cycle DOI

Yan‐Ping Gao,

Jiang‐Tao Lu,

Huijie Zhang

et al.

Biotechnology and Bioengineering, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 26, 2025

ABSTRACT Chinese hamster ovary (CHO) cells represent the most widely utilized host system for industrial production of high‐quality recombinant protein therapeutics. Novel CHO cell line development is achieved through genetic and cellular engineering approaches, effectively addressing limitations such as clonal variation productivity loss during culture. Previous studies have established that MAT2A inhibition in tumor promotes expression cyclin‐dependent kinase inhibitor p21, inducing antitumor activity. Notably, p21 induction has been shown to enhance by triggering cycle arrest. In this study, we identified a potential regulatory target, showing significant differential transfected with elevated versus diminished production. To investigate phenomenon, generated knockdown (shMAT2A) evaluated their output. Results demonstrated silencing enhanced recombiant protein/antibody 1.73‐/1.70‐fold suppression CyclinD1, thereby activating G1 phase Furthermore, pharmacological using small molecules increased volume, boosted metabolic activity, improved specific antibody 1.88‐/2.16‐fold cells. These findings advance our understanding MAT2A‐mediated mechanisms provide strategic framework developing high‐efficiency systems.

Language: Английский

Citations

0
Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management DOI Creative Commons

Wang Dui,

Zhao Xiao-bin,

Zhang Haifeng

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 20, 2025

RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted lot of research on the application technology in treatment CVDs. Despite hurdles off-target effects immune responses, clinical trial outcomes encouraging. This review synthesizes current progress CVDs, examining their mechanisms, advantages, challenges delivery safety. We highlight potential personalized medicine, combination artificial intelligence (AI) bioinformatics advancing therapeutics. The future CVDs is poised significant impact, necessitating continued interdisciplinary collaboration to optimize these treatments ensure patient safety efficacy.

Language: Английский

Citations

0
Critical analysis of descriptive microRNA data in the translational research on cardioprotection and cardiac repair: lost in the complexity of bioinformatics DOI Creative Commons
Mariann Gyöngyösi,

Julia Guthrie,

Ena Hašimbegović

et al.

Basic Research in Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Language: Английский

Citations

0
RNA-based therapies for neurodegenerative disease: Targeting molecular mechanisms for disease modification DOI

Vishal Bhati,

Sonima Prasad,

Atul Kabra

et al.

Molecular and Cellular Neuroscience, Journal Year: 2025, Volume and Issue: unknown, P. 104010 - 104010

Published: May 1, 2025

Language: Английский

Citations

0
The Role of Artificial Intelligence in Drug Discovery and Pharmaceutical Development: A Paradigm Shift in the History of Pharmaceutical Industries DOI

Nithin Vidiyala,

Pavani Sunkishala,

Prashanth Parupathi

et al.

AAPS PharmSciTech, Journal Year: 2025, Volume and Issue: 26(5)

Published: May 13, 2025

Language: Английский

Citations

0
Molecular mechanisms of lncRNA NEAT1 in the pathogenesis of liver-related diseases, with special focus on therapeutic approaches DOI

Ya‐Hui Wang,

Gaurav Sanghvi, Suhas Ballal

et al.

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 269, P. 155867 - 155867

Published: Feb. 26, 2025

Language: Английский

Citations

0
Alternative Splicing in Autism Spectrum Disorder: Recent Insights from Mechanisms to Therapy DOI Creative Commons
Michael Zheng,

Nengcheng Bao,

Zhechao Wang

et al.

Asian Journal of Psychiatry, Journal Year: 2025, Volume and Issue: unknown, P. 104501 - 104501

Published: April 1, 2025

Alternative splicing (AS) is a vital and highly dynamic RNA regulatory mechanism that allows single gene to generate multiple mRNA protein isoforms. Dysregulation of AS has been identified as key contributor the pathogenesis autism spectrum disorders (ASD). A comprehensive understanding aberrant mechanisms their functional consequences in ASD can help uncover molecular basis disorder facilitate development therapeutic strategies. This review focuses on major events regulators associated with ASD, highlighting roles linking defective pathogenesis. In addition, discussion how emerging technologies, such long-read sequencing, single-cell spatial transcriptomics CRISPR-Cas systems are offering novel insights into role presented. Finally, splicing-based strategies evaluated, emphasizing potential address unmet clinical needs treatment.

Language: Английский

Citations

0